Saura C, Cortes J, Modi S, Kim SB, et al. Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. Ann Oncol 2025 Nov 17:S0923-7534(25)06265-9. doi: 10.1016/j.annonc.2025.
PMID: 41260262